Avant l'administration du traitement par COTELLIC en association avec le vémurafénib la présence d'un mélanome à mutation BRAF V600 doit être confirmée par un
Cotellic PM F
5 jan. 2018 As COTELLIC is used in combination with vemurafenib refer also to the ZELBORAF® (vemurafenib). Product Monograph.
Cotellic PM E
28 août 2015 Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma ...
cotellic epar product information en
COTELLIC® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K.
s lbl
1 sept. 2017 COTELLIC® product monograph. Mississauga Ontario; 3 February 2017. BC Cancer Agency Cancer Drug Manual©. Page 6 of 6. Cobimetinib.
Cobimetinib monograph Sep
25 nov. 2020 (Cotellic). Unresectable or metastatic melanoma with a BRAF V600E or. V600K mutation. 20 mg tablets. 63 tablets/28 days vemurafenib.
zanubrutinib Brukinsa
Drug Monograph. Drug Name Mechanism of Action and Pharmacokinetics
cobimetinib ?download=
5 jan. 2018 COTELLIC is used to treat adult patients with a type of skin cancer ... Find the full product monograph that is prepared for healthcare ...
Cotellic PM CIE
21 juil. 2022 TECENTRIQ® indicated for: • in combination with carboplatin and etoposide for the first-line treatment of adult patients.
Tecentriq PM CIE
30 jui. 2016 pCODR Final Clinical Guidance Report – Cobimetinib (Cotellic) for Metastatic Melanoma. pERC Meeting: April 21 2016; pERC Reconsideration ...
pcodr cobimetinib cotellic metmela fn cgr